These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 32292448)

  • 1. Efficacy of Liraglutide in clinical practice: Single centre experience.
    Rashid MO; Jabeen S; Khoja A; Islam N
    Pak J Med Sci; 2020; 36(3):432-437. PubMed ID: 32292448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical experience with Liraglutide in 196 patients with type 2 diabetes from a tertiary care center in India.
    Kaur P; Mishra SK; Mithal A; Saxena M; Makkar A; Sharma P
    Indian J Endocrinol Metab; 2014 Jan; 18(1):77-82. PubMed ID: 24701434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF; Mannucci E; Ahrén B
    Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucagon-Like Peptide-1 Receptor Agonist Utilization in Type 2 Diabetes in Japan: A Retrospective Database Analysis (JDDM 57).
    Ishigaki Y; Strizek A; Aranishi T; Arai N; Imaoka T; Cai Z; Maegawa H
    Diabetes Ther; 2021 Jan; 12(1):345-361. PubMed ID: 33300091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A retrospective, case-note survey of type 2 diabetes patients prescribed incretin-based therapies in clinical practice.
    Evans M; McEwan P; O'Shea R; George L
    Diabetes Ther; 2013 Jun; 4(1):27-40. PubMed ID: 23225378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes Mellitus: Data from a Real-World Study in Spain.
    Norrbacka K; Sicras-Mainar A; Lebrec J; Artime E; Díaz S; Tofé-Povedano S; Hernández I; Romera I
    Diabetes Ther; 2021 May; 12(5):1535-1551. PubMed ID: 33860927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.
    Nauck MA; Quast DR; Wefers J; Meier JJ
    Mol Metab; 2021 Apr; 46():101102. PubMed ID: 33068776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Design and Baseline Characteristics.
    García-Pérez LE; Boye KS; Rosilio M; Jung H; Heitmann E; Norrbacka K; Federici MO; Gentilella R; Guerci B; Giorgino F; Aigner U; Sapin H
    Diabetes Ther; 2021 Jul; 12(7):1929-1946. PubMed ID: 34097244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.
    Pratley R; Amod A; Hoff ST; Kadowaki T; Lingvay I; Nauck M; Pedersen KB; Saugstrup T; Meier JJ;
    Lancet; 2019 Jul; 394(10192):39-50. PubMed ID: 31186120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term impact of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight and glycemic control in Japanese type 2 diabetes: an observational study.
    Inoue K; Maeda N; Fujishima Y; Fukuda S; Nagao H; Yamaoka M; Hirata A; Nishizawa H; Funahashi T; Shimomura I
    Diabetol Metab Syndr; 2014; 6(1):95. PubMed ID: 25237400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Effectiveness of Liraglutide in Association with Patients' Baseline Characteristics in Real-Life Setting in Croatia: An Observational, Retrospective, Multicenter Study.
    Berkovic MC; Bilic-Curcic I; Herman Mahecic D; Gradiser M; Grgurevic M; Bozek T
    Diabetes Ther; 2017 Dec; 8(6):1297-1308. PubMed ID: 29076038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective Analysis of an Insulin-to-Liraglutide Switch in Patients with Type 2 Diabetes Mellitus.
    Bruinstroop E; Meyer L; Brouwer CB; van Rooijen DE; van Dam PS
    Diabetes Ther; 2018 Jun; 9(3):1369-1375. PubMed ID: 29779196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of the glucagon-like peptide-1 analogue liraglutide versus placebo treatment on circulating proglucagon-derived peptides that mediate improvements in body weight, insulin secretion and action: A randomized controlled trial.
    Kim SH; Abbasi F; Nachmanoff C; Stefanakis K; Kumar A; Kalra B; Savjani G; Mantzoros CS
    Diabetes Obes Metab; 2021 Feb; 23(2):489-498. PubMed ID: 33140542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term efficacy of liraglutide in Indian patients with Type 2 diabetes in a real-world setting.
    Kaur P; Mahendru S; Mithal A
    Indian J Endocrinol Metab; 2016; 20(5):595-599. PubMed ID: 27730066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First fixed-ratio combination of insulin degludec and liraglutide for the treatment of type 2 diabetes.
    Rendell M
    Drugs Today (Barc); 2015 Mar; 51(3):185-96. PubMed ID: 25876562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exenatide BID and liraglutide QD treatment patterns among type 2 diabetes patients in Germany.
    Miller LA; Burudpakdee C; Zagar A; Bhosle M; Reaney M; Schabert VF; Bruhn D
    J Med Econ; 2012; 15(4):746-57. PubMed ID: 22443463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment Patterns and Persistence With GLP-1 RA Treatments Among Patients With Type 2 Diabetes in France: A Retrospective Cohort Analysis.
    Zimner Rapuch S; Divino V; Norrbacka K; Boye K; Lebrec J; Rosilio M; DeKoven M; Guerci B
    Diabetes Ther; 2021 May; 12(5):1553-1567. PubMed ID: 33864629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liraglutide Effect on Weight, Glycated Hemoglobin, and Blood Pressure: A Single-Center Experience in the Eastern Province of Saudi Arabia.
    Alsafwani DM; Alotaibi HN; Alzaid JA; Alghamdi A; Almakhaita HM
    Cureus; 2022 Mar; 14(3):e23554. PubMed ID: 35371841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
    Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Effectiveness and Safety of Once-Weekly GLP-1 Receptor Agonist Dulaglutide as Add-On to Metformin or Metformin Plus Insulin Secretagogues in Obesity and Type 2 Diabetes.
    Mirabelli M; Chiefari E; Tocci V; Caroleo P; Giuliano S; Greco E; Luque RM; Puccio L; Foti DP; Aversa A; Brunetti A
    J Clin Med; 2021 Mar; 10(5):. PubMed ID: 33801192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.